Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

详细信息    查看全文

• 作者：Zsolt Szabo ; Esther Mena ; Steven P. Rowe ; Donika Plyku…
• 关键词：PSMA ; PET ; Prostate cancer ; Molecular imaging ; Fluorine ; 18
• 刊名：Molecular Imaging and Biology
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：17
• 期：4
• 页码：565-574
• 全文大小：1,312 KB
• 参考文献：1.Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64:9-9PubMed View Article
  2.Shinohara K, Wheeler TM, Scardino PT (1989) The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol 142:76-2PubMed
  3.Hricak H, Dooms GC, Jeffrey RB et al (1987) Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 162:331-36PubMed View Article
  4.Scheidler J, Hricak H, Vigneron DB et al (1999) Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—clinicopathologic study. Radiology 213:473-80PubMed View Article
  5.Blomqvist L, Carlsson S, Gjertsson P et al (2014) Limited evidence for the use of imaging to detect prostate cancer: a systematic review. Eur J Radiol 83:1601-606PubMed View Article
  6.Turlakow A, Yeung HW, Pui J et al (2001) Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 161:1003-007PubMed View Article
  7.Hofer C, Laubenbacher C, Block T (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36:31-5PubMed View Article
  8.Nunez R, Macapinlac HA, Yeung HW et al (2002) Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43:46-5PubMed
  9.Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199:751-56PubMed View Article
  10.Hricak H, Choyke PL, Eberhardt SC et al (2007) Imaging prostate cancer: a multidisciplinary perspective. Radiology 243:28-3PubMed View Article
  11.Lawrentschuk N, Davis ID, Bolton DM, Scott AM (2006) Positron emission tomography and molecular imaging of the prostate: an update. BJU Int 97:923-31PubMed View Article
  12.de Jong IJ, Pruim J, Elsinga PH et al (2003) 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32-8, Discussion 8- PubMed View Article
  13.Picchio M, Messa C, Landoni C et al (2003) Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 169:1337-340PubMed View Article
  14.Scattoni V, Picchio M, Suardi N et al (2007) Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 52:423-29PubMed View Article
  15.Greco C, Cascini GL, Tamburrini O (2008) Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? Prostate Cancer Prostatic Dis 11:121-28PubMed View Article
  16.Chang SS (2004) Overview of prostate-specific membrane antigen. Rev Urol 6(Suppl 10):S13–S18PubMed Central PubMed View Article
  17.Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326-34PubMed View Article
  18.Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81-5PubMed
  19.Mease RC, Dusich CL, Foss CA et al (2008) N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 14:3036-043PubMed Central PubMed View Article
  20.Cho SY, Gage KL, Mease RC et al (2012) Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 53:1883-891PubMed Central PubMed View Article
  21.Banerjee SR, Pullambhatla M, Byun Y et al (2010) 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 53:5333-341PubMed Central PubMed View Article
  22.Eder M, Schafer M, Bauder-Wust U et al (2012) 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688-97PubMed View Article
  23.Baur B, Solbach C, Andreolli E et al (2014) Synthesis, radiolabelling and in vitro characterization of the gallium-68-, yttrium-90- and lutetium-177-labelled PSMA ligand, CHX-A-DTPA-DUPA-Pep. Pharmaceuticals 7:517-29PubMed Central PubMed View Article
  24.Chen Y, Pullambhatla M, Byun Y et al (2011) 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-urei do)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17:7645PubMed Central PubMed View Article
  25.Olberg DE, Arukwe JM, Grace D et al (2010) One step radiosynthesis of 6-[(18)F]fluoronicotinic acid 2,3,5,6-tet
• 作者单位：Zsolt Szabo (1)
  Esther Mena (1)
  Steven P. Rowe (1)
  Donika Plyku (1)
  Rosa Nidal (2)
  Mario A. Eisenberger (2)
  Emmanuel S. Antonarakis (2)
  Hong Fan (1)
  Robert F. Dannals (1)
  Ying Chen (1)
  Ronnie C. Mease (1) (2)
  Melin Vranesic (1)
  Akrita Bhatnagar (1)
  George Sgouros (1) (2)
  Steve Y. Cho (1) (3)
  Martin G. Pomper (1) (2)
  
  1. The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Cancer Research Bldg. 2, Room 492, 1550 Orleans St, Baltimore, MD, 21231, USA
  2. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA
  3. Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  
• 刊物主题：Imaging / Radiology;
• 出版者：Springer US
• ISSN：1860-2002

文摘

Purpose Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [18F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Procedures Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM. Results No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUVmax up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [18F]DCFPyL was 0.0139?mGy/MBq or 5?mGy (0.5?rem) from an injected dose of 370?MBq (10?mCi). Conclusions [18F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [18F]DCFPyL is similar to that from other PET radiotracers.